Genmab completes share buy-back program, repurchases 2.2 million shares

COPENHAGEN - Danish biotechnology company Genmab A/S (NASDAQ:GMAB), currently valued at $12.65 billion and maintaining a "GREAT" financial health score according to InvestingPro, announced Monday the completion of its share buy-back program, which concluded on June 26, 2025, ahead of its scheduled July 10 end date.

The company repurchased a total of 2.2 million shares as planned, with a total value of approximately 2.86 billion Danish kroner (DKK). The final transactions of the program took place between June 23-26, 2025, during which Genmab acquired 118,789 shares for approximately 157.2 million DKK. InvestingPro analysis confirms management’s aggressive share buyback strategy, reflecting confidence in the company’s future prospects.

Following the completion of the program, Genmab now holds 2,651,727 treasury shares, representing 4.13% of its total share capital and voting rights.

The buy-back program, initially announced on March 25, 2025, was implemented to reduce the company’s capital and to fulfill obligations under its Restricted Stock Unit program. The repurchases were conducted in accordance with European Union regulations, including the Market Abuse Regulation and the Safe Harbour Regulation.

Transactions were executed across multiple trading platforms, including XCSE (Nasdaq Copenhagen), BCXE, AQEU, and TQEX, with the majority of shares in the final week acquired through XCSE.

Genmab, established in 1999 and headquartered in Copenhagen, focuses on developing antibody therapeutics for cancer and other serious diseases. The company has operations across North America, Europe, and Asia Pacific. With a strong current ratio of 5.34 and more cash than debt on its balance sheet, Genmab maintains robust financial flexibility. The company has demonstrated impressive revenue growth of 25.43% over the last twelve months.Discover more insights about Genmab’s financial health and growth potential with InvestingPro, which offers 8 additional exclusive ProTips and comprehensive analysis through the Pro Research Report.

The information in this article is based on a company press release statement from Genmab.

In other recent news, Genmab A/S has disclosed key updates on its financial and operational activities. The biotechnology company announced details of its share buy-back program, conducted under the authorization of its board of directors, which aims to adjust its capital structure and return value to shareholders. Specifics of the transactions, including the number of shares repurchased and prices paid, are available in Genmab’s SEC filings. Additionally, Genmab has granted 3,320 restricted stock units and 3,636 warrants to its employees as part of a long-term incentive plan, aligning employee interests with those of shareholders. The restricted stock units and warrants have specific vesting conditions and are a common practice to incentivize and retain key talent. In a separate development, analysts at Leerink Partners have raised Genmab’s stock price target to $32 from $29, maintaining an Outperform rating. This adjustment follows the promising updated Rina-S data presented at the ASCO Annual Meeting, supporting plans for a Phase III trial. These recent developments reflect Genmab’s ongoing efforts to enhance shareholder value and advance its clinical research.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.